NCT07287917 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT07287917
Title	Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Aminex Therapeutics, Inc.
Indications	skin melanoma Advanced Solid Tumor Her2-receptor negative breast cancer
Therapies	AMXT1501 + Capivasertib + Eflornithine + Fulvestrant AMXT1501 + Eflornithine + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
Lumi Research	RECRUITING	Houston	Texas	77090	United States	Details
Laguna Clinical Research Associates	RECRUITING	Laredo	Texas	78041	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT07287917Clinical Trial Detail